Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
UCB Biopharma SRL
Kenneth B Gordon; Peter Foley; James G Krueger; Andreas Pinter; Kristian Reich; Ronald Vender; Veerle Vanvoorden; Cynthia Madden; Katy White; Christopher Cioffi; Andrew Blauvelt